Hyperoxaluria - A Pipeline Analysis Report

Overview of the drug development pipeline for hyperoxaluria

Hyperoxaluria is a state of disordered metabolism characterized by an increased urinary excretion of oxalate. The daily oxalate excretion in healthy individuals ranges between 10 mg and 40 mg per 24 hours. Concentrations exceeding 40-45 mg per 24 hours are considered as clinical hyperoxaluria. Hyperoxaluria is of several types including primary hyperoxaluria, oxalosis, enteric hyperoxaluria, hyperoxaluria related to eating high-oxalate foods. The worldwide prevalence of primary hyperoxaluria is estimated to affect one in 58,000 individuals. One estimate places the prevalence of primary hyperoxaluria type I at 1-3 cases per 1,000,000 people in the general population, and the incidence at one case per 120,000 live births per year in Europe. Hyperoxaluria is uncommon, though it can be found in about 20% of individuals with kidney stones. As a result, owing to the rising incidences of hyperoxaluria, the drug development for hyperoxaluria is expected to rise considerably during the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for hyperoxaluria. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperoxaluria. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Allena Pharmaceuticals
• Captozyme
• Dicerna Pharmaceuticals
• Intellia Therapeutics

Therapeutic assessment of the drug development pipeline for hyperoxaluria by route of administration

• Oral
• Subcutaneous

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for hyperoxaluria by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for hyperoxaluria are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for hyperoxaluria?
• What are the companies that are currently involved in the development of drug molecules for hyperoxaluria?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.